2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1210

Genetic, Environmental, and Serologic Risk Factors for Inflammatory Joint Signs Among First-Degree Relatives without Rheumatoid Arthritis in a Prospective Cohort
Abstract Number: 2995

Genome Wide Analysis in Scleroderma Renal Crisis: Defining Genetic Risk in Patients with RNA Polymerase III Auto-Antibodies
Abstract Number: 3088

Genome Wide Expression Analyses Reveal Potentially Novel Drug Targets in Fibromyalgia
Abstract Number: 1622

Genome-Wide Association Analysis and Whole Genome Sequencing Identify Variants Associated with Radiographic Severity of Rheumatoid Arthritis in African Americans
Abstract Number: 2099

Genome-Wide Association Study of Clinically-Defined Gout Identifies Multiple Risk Loci: A Clue for Future Companion Diagnostics of Gout
Abstract Number: 1623

Genome-Wide Association Study of DNA Methylation in Th1 and Th17 Cells in Rheumatoid Arthritis
Abstract Number: 110

Genome-Wide DNA Epigenetic Profiling of Monozygotic Twins[L1] Discordant for ACPA or ACPA-Positive Rheumatoid Arthritis Reveals Novel Associated Genes
Abstract Number: 3128

Genome-Wide DNA Methylation Analysis in Blood and Dermal Fibroblasts from Twin Pairs Discordant for Systemic Sclerosis
Abstract Number: 1255

Genome-Wide DNA Methylation Patterns in CD4+ T Reveal Significant Contribution of DNA Methylation to Rheumatoid Arthritis
Abstract Number: 1257

Genome-Wide DNA Methylation Signatures of Salivary Gland Inflammation in Sjögren’s Syndrome
Abstract Number: 566

Genome-Wide Trans-Ancestry Meta-Analysis of Herpes Zoster in RA and Pso Patients Treated with Tofacitinib
Abstract Number: 97

Genomic Sequencing of Uric Acid Metabolizing and Clearing Genes in Relationship to Xanthine Oxidase Inhibitor Dose
Abstract Number: 721

Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Systemic Lupus Erythematosus
Abstract Number: 2696

Geography and Association Between Patient Reported Outcomes and Disease Activity (DAS28) Components in Patients with Rheumatoid Arthritis, Among 17 Countries
Abstract Number: 1555

Geography and the Influence of Comorbidity on the Prevalence of Depression in Patients with Rheumatoid Arthritis,a Study Across Seventeen Countries

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].